SpringWorks Therapeutics, Inc. (SWTX)
Market Cap | 1.92B |
Revenue (ttm) | n/a |
Net Income (ttm) | -259.31M |
Shares Out | 62.38M |
EPS (ttm) | -5.20 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 502,885 |
Open | 29.94 |
Previous Close | 30.07 |
Day's Range | 29.94 - 31.27 |
52-Week Range | 13.60 - 65.92 |
Beta | 0.57 |
Analysts | Buy |
Price Target | 65.79 (+113.54%) |
Earnings Date | Feb 23, 2023 |
About SWTX
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clini... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for SWTX stock is "Buy." The 12-month stock price forecast is $65.79, which is an increase of 113.54% from the latest price.
News

SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

Kaskela Law LLC Announces Investigation of SpringWorks Therapeutics, Inc. (SWTX) and Encourages Long-Term SWTX Investors to Contact the Firm
Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - Kaskela Law LLC announces that it is investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) on behalf of the company's long-term i...

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference
STAMFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 –

Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
CONCORD, Mass. , Nov. 1, 2022 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelera...

Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 211.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
STAMFORD, Conn., Sept. 29, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...

SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.

SpringWorks Therapeutics Announces $225 Million Private Placement Financing
Strengthens Financial Position to Over $600 Million in Cash, Cash Equivalents and Marketable Securities, Upon Closing of the Financing Strengthens Financial Position to Over $600 Million in Cash, Cash...

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
- SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments -

SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints –

SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference
STAMFORD, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors
STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in SpringWorks Therapeutics, Inc. with Losses to Contact the Firm
Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spri...

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a s...

SpringWorks Therapeutics to Present Progress Across the Company's Targeted Oncology Portfolio at Virtual R&D Day
-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Oncology Review (RTOR) Program, Expected in Second Half of 2022 -- -- New Phase 2 Study Announced to ...

SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
STAMFORD, Conn., June 09, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

Here is why SpringWorks Therapeutics jumped 20%
SpringWorks Therapeutics Inc. (NASDAQ: SWTX) stock jumped 20% after the clinical-stage company focusing on life-changing treatment for cancer, and rare diseases announced encouraging results from its ...

Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week's American Society of Cli...

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting
- Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients with Relapsed or Refractory Multiple Myeloma -

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

Why SpringWorks Shares Are Soaring Today Premarket
SpringWorks Therapeutics Inc (NASDAQ: SWTX) has announced positive topline results from the DeFi Phase 3 trial evaluating nirogacestat in adult patients with progressing desmoid tumors. Desmoid tumors...

SpringWorks shares jump 14%; company plans to seek FDA approval for desmoid tumor therapy this year
Shares of SpringWorks Therapeutics Inc. SWTX, +2.18% were up 14.9% in premarket trading on Tuesday after the company said a late-stage clinical trial evaluating its treatment for patients with progres...